Logo

Formycon and Bioeq Report Submission of BLA to the US FDA for FYB201 (biosimilar- ranibizumab)

Share this

Formycon and Bioeq Report Submission of BLA to the US FDA for FYB201 (biosimilar- ranibizumab)

Shots:

  • Formycon and partner Bioeq have submitted a BLA for FYB201 (biosimilar referencing Lucentis) to the FDA
  • Lucentis is a mAb fragment used to treat various types of macular-degenerative diseases and other serious eye diseases. If approved- Coherus will commercialize FYB201 in the US
  • Currently- Formycon has four biosimilars while Coherus also has a biosimilar bevacizumab CHS-305 which is currently under development in collaboration with Innovent

Ref: Formycon | Image: Formycon

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Related News/Articles

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions